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Abstract: Serotonin receptor 2A (HTR2A) is an important signalling factor implicated in cognitive
functions and known to be associated with schizophrenia. The biological significance of HTR2A
in schizophrenia remains unclear as molecular analyses including genetic association, mRNA
expression and methylation studies have reported inconsistent results. In this study, we examine
HTR2A expression and methylation and the interaction with HTR2A polymorphisms to identify
their biological significance in schizophrenia. Subjects included 25 schizophrenia and 25 control
post-mortem brain samples. Genotype and mRNA data was generated by transcriptome sequencing.
DNA methylation profiles were generated for CpG sites within promoter-exon I region. Expression,
genotype and methylation data were examined for association with schizophrenia. HTR2A mRNA
levels were reduced by 14% (p = 0.006) in schizophrenia compared to controls. Three CpG
sites were hypermethylated in schizophrenia (cg5 p = 0.028, cg7 p = 0.021, cg10 p = 0.017) and
HTR2A polymorphisms rs6314 (p = 0.008) and rs6313 (p = 0.026) showed genetic association with
schizophrenia. Differential DNA methylation was associated with rs6314 and rs6313. There was
a strong correlation between HTR2A DNA methylation and mRNA expression. The results were
nominally significant but did not survive the rigorous Benjamini-Hochberg correction for multiple
testing. Differential HTR2A expression in schizophrenia in our study may be the result of the
combined effect of multiple differentially methylated CpG sites. Epigenetic HTR2A regulation may
alter brain function, which contributes to the development of schizophrenia.
Keywords: HTR2A; schizophrenia association; mRNA expression; DNA methylation; rs6314;
rs6313; epigenetics
1. Introduction
The serotonin receptor 2A (HTR2A) is an important signalling factor implicated in high-order
cognition [1,2]. It is found expressed abundantly in the glutamatergic interneurons and
gamma-aminobutyric acid (GABA)-ergic neurons in the prefrontal cortex and hippocampal regions and
both neurotransmission systems are known to be involved in the pathogenesis of schizophrenia [3–6].
The serotonin receptor 2A gene (HTR2A) was shown to influence prefrontal cognition via binding
of receptor agonists including quipazine and 3-trifluoromethylphenylpiperazine [7]. Deficits in
prefrontal cognitive function (such as executive roles and working memory) are a core feature of
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schizophrenia [8]. In a later review, it was suggested that HTR2A antagonists were used as treatments
aimed to improve cognitive function, although the efficacy of HTR2A antagonists has yet to be
unequivocally established [9]. Overall, this evidence strongly suggests a role for HTR2A in the
pathogenesis of schizophrenia.
Based on pharmacological and expression studies, results suggest that the downregulated
HTR2A mRNA expression and reduction of receptor density or activity are associated with
schizophrenia [7,10–12]. According to a review by Selvaraj et al., nine frontal cortex studies found
54 patients with decreased HTR2A receptor activity in schizophrenia [13]. However, one cohort
of antipsychotic-free patients revealed upregulation of HTR2A receptor density in the prefrontal
regions [14,15]. Maple et al. suggested that stress-induced expression of HTR2A as an adaptive
function and is disrupted in schizophrenia patients. Although the induced expression of HTR2A
may appear beneficial, along with the majority of the evidence pointing to the increased expression
of HTR2A in healthy individuals, it is rather paradoxical that antipsychotics block the action of
HTR2A [16]. This paradox is further highlighted by the fact that hallucinogens (such as lysergic acid
diethylamide) are HTR2A agonists, while atypical antipsychotics are antagonists [16]. While clozapine
can be considered an antagonist, it eventually triggers downstream activation of Akt, similar to the
effect of serotonin agonists via different mechanisms [17]. Although such inconsistency remains to be
clarified, these studies suggest an association between the dysregulation of HTR2A mRNA expression
and schizophrenia.
The HTR2A polymorphism, rs6314 is a non-synonymous DNA variant located in exon 3 that
results in a His452Tyr substitution. Studies suggest that rs6314 may have an effect on calcium
signalling and mobilisation and altered activation of phospholipases C and D, possibly resulting
in reduced receptor activity [18,19], but it is not clear how this impacts on neurotransmission or
susceptibility to schizophrenia. Serretti et al. reviewed a number of association studies between
rs6314 and schizophrenia and found inconsistent results [20]. Decreased HTR2A expression was
associated with rs6314 in one study [21] and the polymorphism was also associated with a number of
endophenotypes including hippocampal volume and activity [22,23], memory [23,24], and clozapine
treatment response in patients with schizophrenia [25].
A synonymous HTR2A polymorphism, rs6313 (T102C) is a well-studied variant that was found
to be in linkage disequilibrium (LD) with another functional polymorphism (rs6311) known to alter
HTR2A promoter activity [26]. A number of studies have either found [12,27,28] or failed to find an
association [10,29] between rs6313 and schizophrenia. Poorer cognitive performance was found to be
associated with the T-allele of rs6313 [30]. However, another study found that poorer visual sustained
attention was associated with the C-allele [31]. These different findings may be due to significant ethnic
differences between the two studies. Binding activity or receptor density of HTR2A in the brain [32,33]
and differential expression in the temporal cortex [12] are associated with the rs6313 polymorphism.
Although the biological mechanism of rs6313 and rs6314 remains unclear, the findings suggest that
both polymorphisms are good candidates for schizophrenia risk.
DNA methylation is thought to be an important epigenetic mechanism in schizophrenia [34]
as environmental influences on HTR2A DNA methylation are associated with infant neurobehavioural
outcomes [35]. For HTR2A, the majority of the DNA methylation activity occurs within the promoter
and exon I, but there is little DNA methylation activity in other regions of the gene. HTR2A
CpG sites were either hypermethylated (near rs6311, at position −1438 of the promoter region)
or hypomethylated (near rs6313, at position 102 of exon I) in the prefrontal cortex of patients
with schizophrenia, potentially resulting in downregulation of HTR2A expression in patients with
schizophrenia [10]. Another study also reported similar results in the saliva of patients with
schizophrenia [36]. Increased DNA methylation at rs6313 in peripheral leukocytes was reported
in major psychosis patients with suicidal tendency [37], suggesting the potential involvement of
HTR2A promoter hypermethylation in psychosis. Based on the literature, there is strong evidence of
schizophrenia-specific DNA methylation changes in HTR2A that influence mRNA expression.
While it is clear that DNA methylation alters HTR2A mRNA expression [10,38–40] (apart from
other known factors such as stress, medication and substance use, nutrition history, comorbidities
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and other underlying biological factors), HTR2A polymorphisms have also been reported to influence
mRNA expression, possibly by altering recognition of CpG sites. One study [21] found that HTR2A
rs6314 was associated with mRNA expression changes, although the effects of promoter DNA
methylation were not taken into account. In this study, we investigated the role of HTR2A in
schizophrenia by examining rs6314 and rs6313 genotype, DNA methylation, and the expression
of HTR2A mRNA in prefrontal cortex samples of schizophrenia patients.
2. Materials and Methods
2.1. Samples
The brain tissue was provided by the Human Brain and Spinal Fluid Resource Centre, Los Angeles,
California (courtesy of James Riehl). The brain tissues were collected from 25 schizophrenia patients
and 25 healthy controls. Each sample consisted of a 7-mm coronal section that had been quick-frozen,
followed by dissection of the frontal cortex (0.4–1.0 g) from the frozen sections. A summary of sample
age, post-mortem interval (PMI) and gender are shown in Table 1, with complete sample information
detailed in Supplementary Table S1. PMI represents the time interval from the death of a patient to
the quick-freezing of the brain section. All but two of the patients with schizophrenia were using
medication at their time of death. Five patients with schizophrenia were identified as suicide victims.
Extraction of RNA and DNA from post-mortem frontal cortex brain tissues was performed at
the UCLA Clinical Microarray Core Laboratory (Los Angeles, CA, USA) using the Roche MagNa
Pure Compact. There were five samples with missing mRNA data due to quality control failure,
data generation failure and insufficient/no RNA content. Two samples had missing DNA methylation
data as they were excluded due to protocol constraints (we could only run 48 samples due to the bead
chip plate format).
Ethics approval for the project was obtained from the Human Research Ethics Committee of the
Queensland University of Technology.
Table 1. Summary of demographic D=details.
Control (n = 23) Schizophrenia (n = 22) t-Test/Chi-Square p-Value
Age, mean (s.d.) 70.2 (9.2) 52.5 (22.7) 0.0022
PMI, mean (s.d.) 14.1 (3.2) 24 (10.6) 0.0003
Sex, male (%) 18 (78) 14 (64) 0.2778
s.d., one standard deviation.
2.2. mRNA Data Generation
Sequencing of total RNA for each sample was performed by the Australian Genome Research
Facility (AGRF). Quality of extracted RNA was assessed by electrophoresis using Agilent Bioanalyzer
RNA 6000 Nano assay (Santa Clara, CA, USA). The percentage of RNA fragments >200 nucleotides
was assessed to determine the appropriate input. Samples with <30% of RNA >200 nucleotides were
excluded. A total of 46 samples passed the initial quality control (QC). Following sample QC, samples
were processed and used to generate HTR2A mRNA sequence data with the TruSeq RNA Access
Sample Preparation Kit as per the manufacturer’s instructions (Illumina, San Diego, CA, USA). Briefly,
total mRNA was firstly fragmented, followed by first and subsequently second strand cDNA synthesis.
The blunt-ended cDNA were 3′-adenylated and ligated with adapters that hybridise to the flow cell.
The adapter-added cDNA were subsequently amplified creating a cDNA library. One sample failed to
generate enough library to proceed to capture hybridisation and was excluded from the final analysis.
A total of 45 samples were further investigated.
Captured libraries were pooled for sequencing. Each pool of libraries was clustered on the
Illumina cBot system (Illumina, San Diego, CA, USA) using HiSeq PE Cluster Kit v4 reagents (Illumina,
San Diego, CA, USA) followed by sequencing on the Illumina HiSeq 2500 system with HiSeq SBS Kit
v4 reagents with 159 cycles (75 base pair paired end reads). Illumina RTA 1.18.61 (Illumina, San Diego,
CA, USA) was used for base calling, quality scoring. Bcl2fastq pipeline 1.8.4 (Illumina, San Diego, CA,
USA) was used for de-multiplexing and FASTQ file generation.
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2.3. mRNA Data Transformation
The total generated sequence reads in FASTQ files were mapped to the human genome
(GRCh38/hg38) using Tophat 2.0.13 [41] to identify sequence reads that align/correspond to the
HTR2A gene. Mapped RNA sequence reads aligned to HTR2A were subsequently counted using
the tool feature Counts from the SubRead package 1.4.6p5 [42] to assign raw non-normalised
read counts to genes (specifically HTR2A). Non-normalised read counts were used for the edgeR
package 3.12.0 [43] to perform quality control and normalisation using the TMM (trimmed mean of
M values) method [44]. Normalised read counts (expressed as reads per kilobase transcript per million
mapped read counts or RPKM) were transformed to log10RPKM using SPSS (Statistical Package for
the Social Sciences) 22 (SPSS, Chicargo, IL, USA).
2.4. Genotyping
Total RNA sequence reads were aligned to GRCh38/hg38 using BWA (Burrows-Wheeler
Alignment) for Illumina version 1.2.3 (Digital Equipment Corporation, Palo Alto, CA, USA). Genotypes
of rs6314 and rs6313 (loci shown in Figure 1) were determined by visualising the aligned sequence
reads using IGV (Integrative Genomics Viewer) version 2.3.52 (Broad Instituite, Cambridge, MA, USA).
Polymorphism quality was further screened for its span within reads with spans at or near ends of
reads excluded due to high sequencing error rates at ends of reads [45].
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Figure 1. HTR2A gene structure showing exons, loci of rs6313 and rs6314, and all 10 selected CpG sites.
2.5. CpG Site Methylation Data Generation and Transformation
Genome-wide DNA methylation was analysed using the Illumina HumanMethylation450 array
that assays more than 485,000 CpG sites across the genome exactly as previously described [34,46].
HTR2A methylation profiles were generated by selecting CpG sites within regions with active DNA
methylation (±500 bp of transcription start site) including the promoter and exon I of HTR2A.
These sites were selected for their loci within DNA regions with rich presence of regulatory
signals/elements based on the UCSC genome browser. The sites were identified as cg20102280,
cg15894389, cg02250787, cg06476131, cg16188532, cg09361691, cg11514288, cg27068143, cg10323433
and cg02027079 as detailed in Table 2 (loci shown in Figure 1). The methylation status for each
site was recorded as a β-value that ranged between 0 and 1, where values close to 1 represent high
levels of methylation and where values close to 0 represent low levels of methylation. β-values were
transformed to logit values or log10(β/1−β) values using SPSS 22.
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Table 2. Details of selected CpG sites.
CpG Site Illumina CpG Site Name Feature Locus
cg1 cg20102280 Exon I chr13:46896658
cg2 cg15894389 Exon I chr13:46896722
cg3 cg02250787 Exon I chr13:46896854
cg4 cg06476131 Exon I chr13:46896917
cg5 cg16188532 Exon I chr13:46896955
cg6 cg09361691 Exon I chr13:46897034
cg7 cg11514288 Exon I chr13:46897062
cg8 cg27068143 Promoter chr13:46897129
cg9 cg10323433 Promoter chr13:46897427
cg10 cg02027079 Promoter chr13:46897570
2.6. Data Analysis
Using the log10RPKM values to represent HTR2A mRNA expression levels and log10(β/1−β)
values to represent CpG site DNA methylation levels, analysis of variance (ANOVA) adjusted for
age and PMI (placing age and PMI variables as covariates) was performed with SPSS 22 to compare
HTR2A mRNA expression differences and DNA methylation differences for the CpG sites between
schizophrenia and control subjects. ANOVA was also used to examine the effect of rs6314 and rs6313
genotypes on HTR2A mRNA expression and DNA methylation of the CpG sites. Linear regression
analysis adjusted for age and PMI was performed using SPSS 22 to correlate HTR2A expression
levels and HTR2A methylation levels. HTR2A mRNA expression and DNA methylation for the
CpG sites were firstly correlated in total samples, followed by correlation in schizophrenia-only and
control-only subjects.
3. Results
3.1. Schizophrenia and HTR2A mRNA Expression
The log10RPKM values were compared between schizophrenia and control subjects using ANOVA.
There was a 14% reduction in HTR2A mRNA expression in patients with schizophrenia compared to
controls (F-value of 8.564 and p-value of 0.006; Figure 2).Genes 2017, 8, 14  6 of 12 
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Figure 2. HTR2A mRNA expression in patients with schizophrenia compared to controls. ANOVA
showing mean expression level and standard error in patients with schizophrenia.
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3.2. Schizophrenia and DNA Methylation
Methylation levels (logit β-values) were compared between schizophrenia and control subjects
using ANOVA for all CpG sites. Three CpG sites, cg5 (F = 5.194, p = 0.028), cg7 (F = 5.753, p = 0.021)
and cg10 (F = 6.155, p = 0.017) were hypermethylated in patients with schizophrenia compared to
controls (Figure 3).
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Figure 3. HTR2A DNA methylation in patients with schizophrenia compared to controls for three CpG
sites, cg5, cg7 and cg10. ANOVA showing mean DNA methylation level and standard error in patients
with schizophrenia (solid dark-grey bar) and controls (solid white bar).
3.3. rs6314 and rs6313 Genotypes
Genotype frequencies were generated for schizophrenia and control subjects (Table 3). No T/T
genotype was present in our samples for rs6314. For rs6314 we observed a significant difference
between the genotype counts of schizophrenia and control subjects (p = 0.008) with an odds ratio (OR)
of 5.7 (C/T as high risk genotype) while no association was detected between rs6313 and schizophrenia
(p = 0.078). Although rs6313 association was not significant, individuals with the T/T genotype had
an OR of 7.0 (p = 0.144). When analysed as a T-recessive trait, rs6313 was found associated with
schizophrenia (p = 0.026) with an OR of 8.4 (T as high risk recessive allele). This suggests the T-allele is
the schizophrenia risk allele for both rs6313 and rs6314 although results should be interpreted with
caution due to the low sample number.
Table 3. Genotype and allele frequencies for rs6314 in schizophrenia and control groups.
Genotype/Allele Schizophrenia Control Chi-Square p-Value Odds Ratio
rs6314 Genotype
C/C 10 19
0.008 5.7
C/T 12 4
T/T 0 0
Total 22 23
rs6314 Allele
C 32 42
0.019 3.9T 12 4
Total 44 46
rs6313 Genotype
C/C 6 7
0.078 –
C/T 9 14
T/T 6 1
Total 21 22
rs6313 Allele
C 21 28
0.201 –T 21 16
Total 42 44
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3.4. HTR2A mRNA Expression and Genotypes
ANOVA was performed to test the association between HTR2A mRNA expression and rs6314
and rs6313 genotypes. We compared the HTR2A mRNA expression between C/C genotypes and C/T
genotypes for all samples, i.e., schizophrenia and control samples were pooled (there were no T/T
genotypes present in our sample for rs6314). No differential expression was observed for either rs6314
(F = 0.160, p = 0.691) or rs6313 (F = 1.690, p = 0.198) genotypes.
3.5. DNA Methylation and Genotypes
For rs6314, ANOVA detected differential methylation between the subjects with C/T genotype
and C/C genotype for cg3 (hypermethylated C/T group, F = 8.645, p = 0.005) and cg8 (hypermethylated
C/T group, F = 5.800, p = 0.021). For rs6313, ANOVA detected differential methylation between C-allele
carriers and subjects with the T/T genotype for cg6 (hypomethylated C-allele carriers, F = 4.184,
p = 0.048).
3.6. Correlation between mRNA Expression and DNA Methylation
Using linear regression, we firstly tested the correlation between HTR2A mRNA expression
and single site DNA methylation for the 10 CpG sites. No significant relationship was detected
(Table S2). When all 10 CpG sites were analysed together, the combined effect of ten CpG sites on
mRNA expression were not significant (R2 = 0.243, p = 0.291) although two CpG sites within the
10-CpG site model, cg2 (B = 0.282, p = 0.045) and cg4 (B = −0.328, p = 0.037) were significant.
We also tested for a correlation between HTR2A mRNA expression and single CpG site
methylation for all 10 CpG sites within patients with schizophrenia as well as control subjects
(Supplementary Table S2). For patients with schizophrenia, a significant correlation was identified for
cg5 (B = 0.525, R2 = 0.196, p = 0.014) for single CpG site analysis. When all 10 CpG sites were analysed
together in patients with schizophrenia, cg5 (B = 0.615, p = 0.007), cg6 (B = −0.695, p = 0.034), cg7
(B = 1.066, p = 0.026) and cg9 (B = −0.745, p = 0.049) were significantly correlated with mRNA
expression with an overall R2 = 0.537 and overall significance of p = 0.008.
For control subjects, a significant correlation was identified for cg9 (B = 0.666, R2 = 0.272,
p = 0.015) for single CpG site analysis. When all 10 CpG sites were analysed together in control
subjects, no significantly correlation with mRNA expression was detected.
4. Discussion
This paper reports a number of complex associations with schizophrenia for the HTR2A gene
that are potentially all interacting with each other. We found association between (1) schizophrenia
and reduced HTR2A mRNA expression; (2) schizophrenia and hypermethylation of HTR2A promoter
CpG sites (cg5, cg7 and cg10); and (3) schizophrenia and HTR2A genotypes for rs6314 and rs6313.
Association was also found between DNA methylation and genotypes of both rs6314 and rs6313.
There was a strong correlation between DNA methylation and mRNA expression in patients
with schizophrenia.
No association was found between rs6314 and mRNA expression. This is consistent with
Blasi et al. [21], who only found a trend of reduced HTR2A mRNA in prefrontal cortex samples
bearing the T-allele of rs6314, but the trend was not significant (p = 0.06). Furthermore, they did not
examine the effects of DNA methylation. The authors suggested, however, that rs6314 could alter
splicing patterns with possible effects on HTR2A expression.
The polymorphism rs6314 was associated with differential methylation at CpG sites cg3 and
cg8, though it is unclear what mechanism might lead to this considering that rs6314 is located 61 kb
from the CpG sites in the promoter-exon I region. This is also consistent with Guhathakurta et al.,
who showed that rs6314 is unlikely to influence DNA methylation activity in the promoter (such as
methylation site at rs6311) due to low LD [47]. Association was also detected between rs6313 and
differential methylation of cg6. The rs6313 polymorphism is only 1.2 kb from cg6, so it is possible that
Genes 2017, 8, 14 8 of 11
it has a proximal effect on the binding of DNA methylases; further studies investigating the biological
function of rs6313 on DNA methylation would clarify the role of rs6313 in schizophrenia.
An interesting observation in the mRNA expression–DNA methylation correlation analysis is
the significant combined effect of all CpG sites detected when only patients with schizophrenia were
analysed. Furthermore, methylation of cg5 and cg9 was correlated with mRNA expression and
associated with schizophrenia. No significant combined effect of all CpG sites was detected when
control-only subjects or pooled subjects (schizophrenia plus control) were analysed. This suggests
that DNA methylation may have an effect on mRNA expression in patients with schizophrenia but
not in control subjects. Perhaps there is little to no significant variation of mRNA expression and
DNA methylation levels between control subjects for a significant correlation to be detected. However,
it is possible that the significant correlation of DNA methylation-mRNA expression detected in
schizophrenia may be a net result of DNA methylation alterations, along with other interacting factors
(including genes, environmental factors and other underlying biological factors). Indeed, Abdolmaleky
et al. found a negative correlation between HTR2A and COMT expression, a positive correlation
between HTR2A and RELN expression, and a negative correlation between HTR2A expression and
RELN promoter DNA methylation [10]. Overall, our results are consistent with those of Abdolmaleky
et al., who reported an inverse relationship between HTR2A mRNA expression and promoter region
DNA methylation.
Our results showed an association between three hypermethylated CpG sites and schizophrenia.
This is consistent with other studies that found hypermethylated DNA within the promoter region
of HTR2A in schizophrenia brains and saliva [10,36], hypermethylated DNA at rs6313 in peripheral
leukocytes in major psychosis patients with suicidal tendency [37] and hypermethylated HTR2A
promoter CpG islands in the blood of patients with borderline personality disorder [48]. It should be
noted that in a study by Abdolmaleky et al. that detected reduced HTR2A mRNA expression in brain
samples, regions within the promoter were hypermethylated while regions near rs6313 within exon I
were hypomethylated. To some extent, this observation is consistent with our findings, where both
positive and negative correlations of DNA methylation-RNA expression are present. This suggests
that the mechanisms regulating mRNA expression in brain are different in the blood and the saliva.
Furthermore, combined CpG-site analysis suggests interaction between multiple CpG-sites resulting
in altered HTR2A mRNA expression.
A limitation to this study is that, after correcting relevant results for multiple testing, they did
not survive their respective thresholds. However, the samples are not completely independent so
correction for multiple testing may not be valid.
This study has concentrated on DNA methylation in the promoter and exon I regions of HTR2A.
Future studies should explore the −3′ region of the gene to investigate methylation alteration in
schizophrenia. These studies should be conducted in relevant brain tissues as it is the organ of major
pathology for schizophrenia. In addition to age and PMI, factors influencing the outcomes of mRNA
expression and DNA methylation including stress, medication and substance use, nutrition history,
comorbidities, ethnogeographic information and other environmental factors should be included in
future studies to further improve the accuracy of the findings.
5. Conclusions
In conclusion, we report that there is an association between schizophrenia and three separate
factors: reduced HTR2A mRNA expression, hypermethylation of HTR2A promoter CpG sites (cg5, cg7
and cg10) and genetic association with HTR2A genotypes for rs6314 and rs6313. The association of the
T-allele of rs6314 and rs6313 with schizophrenia may be due to an alteration in biological mechanisms
other than mRNA expression regulation. The reduced expression of HTR2A mRNA in schizophrenia
patients may be mainly attributed to DNA methylation of CpG sites within the promoter-exon I region,
and possibly influenced by other underlying factors. Therefore, epigenetic HTR2A regulation may
affect brain function, which contributes to the development of schizophrenia.
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